

- Title** Chlorthalidone for Hypertensive Patients
- Agency** HTA Malaysia, Health Technology Assessment Section, Medical Development Division, Ministry of Health Malaysia
Level 4, Block E1, Parcel E, Presint 1,
Federal Government Administrative Center, 62590 Putrajaya, Malaysia
Tel: +603 88831229, Fax: +603 88831230; htamalaysia@moh.gov.my, www.moh.gov.my
- Reference** Technology Review Report – 028/2013, online:
http://www.moh.gov.my/index.php/database_stores/store_view_page/30/238

Aim

To review evidence on the safety, efficacy/effectiveness and cost-effectiveness of Chlorthalidone to reduce cardiovascular events compared with current practice with hydrochlorothiazide.

Conclusions and results

The studies available were of good level but limited evidence to show Chlorthalidone could reduce cardiovascular events in hypertensive patients.

Recommendations (if any)

Although Chlorthalidone seemed to have potential benefit in reducing cardiovascular events in hypertensive patients, Chlorthalidone is not recommended for routine use in management of hypertensive patient in Ministry of Health facilities because Chlorthalidone is not listed in Ministry of Health Drug Formulary (Blue Book) of Malaysia.

Methods

Electronic databases were searched through Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1948 to present, EBM Reviews - NHS Economic Evaluation Database 4th Quarter 2012, EBM Reviews - Cochrane Database of Systematic Reviews 2000 to December 2012 and EBM Reviews - Cochrane Central Register of Controlled Trials December 2012. Searches were also run in PubMed, Horizon Scanning databases, FDA website and INAHTA for published reports. Only studies published within 2000s to 2013 were included in this technology review report.

Further research/reviews required

Chlorthalidone did showed some benefit compared with other diuretics; however cost-effectiveness study is yet to be determined.

Written by

Maharita Ab Rahman, MaHTAS, Malaysia